Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis.
B. Kiberd,¹ K. Tennankore,¹ K. Doucette.²
¹Medicine, Dalhousie University, Halifax, NS, Canada; ²Medicine, University of Alberta, Edmonton, AB, Canada
Some have recommended that HCV+ kidney wait list patients delay HCV treatment with direct acting antiviral agents (DAAs) with the option of receiving an HCV+/HCV-…
2017 American Transplant Congress
Chagas Disease and Outcome in Kidney Transplant.
M. Taylor, A. Martinoia, S. Di PIetrantonio, M. Torres, H. Petrone.
Renal Transplant Unit, CRAI Sur - CUCAIBA, La Plata, Buenos Aires, Argentina
Introduction: Chagas disease is one of the most expanded endemic in Latin America with 8 people from every 10.000.000 being infected. In Argentina its estimated…
2017 American Transplant Congress
Epigenetic Modifications in the Progression to Chronic Renal Allograft Injury.
V. Bontha,¹ D. Maluf,¹ M. Dozmorov,² K. Archer,³ L. Gallon,⁴ V. Mas.¹
¹UVA, Charlottesville; ²VCU, Richmond; ³OSU, Columbus; ⁴NWU, Chicago
Background: The renal allograft is exposed to a milieu of environmental/metabolic stimuli that trigger epigenetic modifications and thereby gene expression patterns which influence function and…
2017 American Transplant Congress
Meta-Analysis of Clinical Significance of Complement Activating Anti-HLA DSA in Kidney Transplantation.
A. Bouquegneau,^1,2 C. Ulloa,¹ O. Aubert,¹ C. Loheac,¹ D. Viglietti,¹ J. Empana,¹ P. Jabre,¹ X. Jouven,¹ C. Lefaucheur,¹ A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²Department of Nephrology, Dialysis and Transplantation, Liège, Belgium
Donor-specific anti-HLA antibodies (DSA) are currently recognized as the major limitation to access transplantation and the first cause of late transplant failures. The effect of…
2017 American Transplant Congress
The Cumulative United States Experience with Transplants (Txs) from Living Donors (LDs): 140,156 LD Txs in 28 Years.
R. Gruessner,¹ M. Laftavi,¹ V. Whittaker,¹ O. Pankwycz,² Z. Acun,¹ A. Gruessner.¹
¹Surgery, SUNY Upstate Medical University, Syracuse, NY; ²Internal Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Solid organ txs from LDs provide better outcome results than from DDs. We analyzed the cumulative US LD tx experience since UNOS inception. The…
2017 American Transplant Congress
The Relationship Between Frailty and Decreased Physical Performance with Death on the Kidney Transplant Waiting List.
E. Lorenz, F. Cosio, S. Bernard, S. Bogard, B. Bjerke, E. Geissler, S. Hanna, W. Kremers, M. Stegall, A. Cheville, N. LeBrasseur.
Mayo Clinic, Rochester
Background: Frailty and decreased physical performance are associated with poor outcomes after kidney transplant. Less is known about their relationship with pre-transplant outcomes. The aim…
2017 American Transplant Congress
Outcomes of Hand Assisted Laparoscopic Right Donor Nephrectomy, Single Center Experience.
A. El-Hinnawi, A. Rajab, R. Pelletier.
Transplant Surgery, The Ohio State Wexner Medical Center, Columbus, OH
Right donor nephrectomy,especially when conducted laparoscopically,has not been accepted by most transplant surgeons because of the consequent short right renal vein and the possible increased…
2017 American Transplant Congress
Release of HMGB1 in Serum and Urine of Brain-Death Donors Is Associated with Delayed Graft Function (DGF) of the Kidney.
A. Zmijewska,¹ J. Chen,¹ J. Locke,² J. Zmijewski,¹ R. Mannon.¹
¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Surgery, University of Alabama at Birmingham, Birmingham, AL
Delayed kidney graft function (DGF) following a kidney transplant is associated with worse graft survival and higher rejection risk. Risk factors for DGF have been…
2017 American Transplant Congress
Analysis of Outcomes in High Risk Kidney Transplants.
E. Liu, M. Aull, J. Lee, S. Kapur.
Kidney and Pancreas Transplantation, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
Background: The new kidney allocation system implemented in 12/2014 utilizes estimated post-transplant survival scores (EPTS) and kidney donor profile index (KDPI) to optimize recipient survival…
2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
B.-H. Shin,¹ S. Ge,¹ J. Mirocha,² D. Thomas,¹ E. Rodriguez,¹ C. Chao,¹ O. Galera,¹ A. Vo,¹ J. Choi,¹ A. Peng,¹ J. Kahwaji,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…